Bethesda Unit (BU): Standardized quantification of neutralizing antibodies. 1 BU = 50% neutralization of normal factor activity.
Bethesda Units (BU)
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Quantifying the strength of neutralizing antibodies (inhibitors) in patients with Haemophilia A or B.
Differentiating between "Low Titre" and "High Titre" responders to guide bypassing agent vs. factor therapy.
Monitoring response to Immune Tolerance Induction (ITI).
Definition of 1 BU
One Bethesda Unit (BU) is defined as the amount of inhibitor that neutralizes 50% of the factor activity in normal pooled plasma after incarnation at 37°C for 2 hours.
Section 2
Formula & Logic
Inhibitor Thresholds
Titre (BU)
Classification
Clinical Strategy
< 0.6
Negative
Standard Factor Replacement.
0.6 - 5.0
Low Titre
May be overcome with high-dose specific factor replacement.
≥ 5.0
High Titre
Usually requires Bypassing Agents (aPCC or rFVIIa) or Emicizumab.
Anamnestic Response
Low Titre responders who do NOT increase their titre after factor exposure are "Low Responders." Those who jump to high titres (>5 BU) after exposure are "High Responders," even if their baseline titre is currently low.
Section 3
Pearls/Pitfalls
Nijmegen Modification
The Nijmegen modification brings the pH of the test plasma to 7.4 and standardizes protein concentration, improving the specificity of the assay for low-level inhibitors.
The 5 BU Pivot
The 5.0 BU threshold is the primary determinant for the success of standard factor replacement. Above this level, the volume of factor required to neutralize the inhibitor usually exceeds safe circulatory limits.
Section 4
Evidence Appraisal
Primary Consensus
A more specific method for the assay of factor VIII inhibitors.
Kasper CK et al. • Thrombosis et Diathesis Haemorrhagica. 1975;34(3):869-72.